Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies.

ABSTRACT: Glioblastoma (GB), an aggressive primary tumor of the central nervous system, represents about 60% of all adult primary brain tumors. It is notorious for its extremely low (~5%) 5-year survival rate which signals the unsatisfactory results of the standard protocol for GB therapy. This issue has become, over time, the impetus for the discipline of bringing novel therapeutics to the surface and challenging them so they can be improved. The cell-based approach in treating GB found its way to clinical trials thanks to a marvelous number of preclinical studies that probed various types of cells aiming to combat GB and increase the survival rate. In this review, we aimed to summarize and discuss the up-to-date preclinical studies that utilized stem cells or immune cells to treat GB. Likewise, we

SUBMITTER: Attia N 

PROVIDER: S-EPMC8750228 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature